SOPH vs. COGT, CRMD, IMNM, CMRX, CDMO, SNDX, AVXL, SION, QURE, and AVBP
Should you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Cogent Biosciences (COGT), CorMedix (CRMD), Immunome (IMNM), Chimerix (CMRX), Avid Bioservices (CDMO), Syndax Pharmaceuticals (SNDX), Anavex Life Sciences (AVXL), Sionna Therapeutics (SION), uniQure (QURE), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.
SOPHiA GENETICS vs. Its Competitors
SOPHiA GENETICS (NASDAQ:SOPH) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.
SOPHiA GENETICS has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Cogent Biosciences has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.
SOPHiA GENETICS has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.
Cogent Biosciences has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -98.51%. SOPHiA GENETICS's return on equity of -63.47% beat Cogent Biosciences' return on equity.
SOPHiA GENETICS presently has a consensus price target of $7.00, indicating a potential upside of 115.38%. Cogent Biosciences has a consensus price target of $16.33, indicating a potential upside of 74.69%. Given SOPHiA GENETICS's higher possible upside, analysts clearly believe SOPHiA GENETICS is more favorable than Cogent Biosciences.
In the previous week, Cogent Biosciences had 21 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 22 mentions for Cogent Biosciences and 1 mentions for SOPHiA GENETICS. Cogent Biosciences' average media sentiment score of 0.85 beat SOPHiA GENETICS's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media.
31.6% of SOPHiA GENETICS shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
SOPHiA GENETICS and Cogent Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get SOPHiA GENETICS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SOPHiA GENETICS Competitors List
Related Companies and Tools
This page (NASDAQ:SOPH) was last updated on 7/8/2025 by MarketBeat.com Staff
Free SOPH Stock Alerts